A Phase I/IIA Study of UV1 Vaccination in Patients With Hormone-sensitive Metastatic Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Jul 2017
At a glance
- Drugs UV 1 (Primary) ; Sargramostim
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms UV1hTERT2012P
- Sponsors Ultimovacs AS
- 10 Jun 2017 Biomarkers information updated
- 04 Nov 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2020.
- 04 Nov 2016 Planned primary completion date changed from 1 Jan 2015 to 1 Jul 2020.